Cycrimine

Cycrimine (trade name Pagitane) is a central anticholinergic drug designed to reduce the levels of acetylcholine in the treatment of Parkinson's disease. Its mechanism of action is to bind to the muscarinic acetylcholine receptor M1.[1]

Cycrimine
Clinical data
License data
ATC code
  • none
Identifiers
IUPAC name
  • 1-Cyclopentyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
ECHA InfoCard100.000.932
Chemical and physical data
FormulaC19H29NO
Molar mass287.447 g·mol−1
3D model (JSmol)
SMILES
  • OC(CCN1CCCCC1)(C2CCCC2)c3ccccc3
InChI
  • InChI=1S/C19H29NO/c21-19(18-11-5-6-12-18,17-9-3-1-4-10-17)13-16-20-14-7-2-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2
  • Key:SWRUZBWLEWHWRI-UHFFFAOYSA-N

Synthesis

Cycrimine synthesis:[2]

See also

References

  1. Usdin E, Efron DH, eds. (1979). Psychotropic Drugs and Related Compounds (2nd ed.). Washington, DC: Pergamon Press. p. 218. ISBN 978-0-08-025510-1. OCLC 715151908.
  2. Denton JJ, Schedl HP, Lawson VA, Neier WB (1950). "Antispasmodics. VII.1 Additional Morpholinyl and Piperidyl Tertiary Alcohols". Journal of the American Chemical Society. 72 (8): 3795–3796. doi:10.1021/ja01164a127.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.